India's Unique Legal Framework for Psilocybin Mushroom Research: An Unprecedented Opportunity in Psychiatric Therapeutics.
Ashlyn Tom, B. Sai Chaitanya Reddy, Manik Inder Singh Sethi, Suresh Bada Math
Indian Journal of Psychological Medicine February 5, 2026 DOI: 10.1177/02537176261416347 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Psilocybin Psychedelic-assisted therapy |
| Keywords | India drug policy Whole-mushroom research |
| Key points | Argues that the entourage effect, while well documented in cannabis research, remains a hypothesis requiring validation in psilocybin mushrooms, and that whether multiple bioactive compounds produce synergistic effects distinct from isolated psilocybin is an unresolved empirical question. The authors contend this uncertainty, alongside factors unique to India, creates a distinctive position for the country. |
Abstract
The “entourage effect,” well-documented in cannabis research, remains a hypothesis requiring validation in psilocybin mushrooms. Whether the complex interplay among multiple bioactive compounds (including psilocybin, psilocin, baeocystin, norbaeocystin, aeruginascin, and various alkaloids) produces synergistic effects distinct from those of isolated psilocybin remains a critical empirical question that reflects broader scientific uncertainty. 6 This uncertainty, however, is precisely where India’s distinctive position emerges from a convergence of factors not present in most other jurisdictions.